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Background: No molecularly driven strategy against KRAS demonstrated convincing
activity in clinical trials. The introduction of immune checkpoints inhibitors (IO) rep-
resents a paradigm shift in treatment of NSCLC without gene target. Considering the
association with smoke, the high mutational burden, the high PDL1 expression and the
abundance of T-cell infiltrating lymphocyte, KRAS mutant tumors have been consid-
ered an attractive target for IO.
Methods: Patients (pts) with stage IV NSCLC harboring KRAS mutation treated with
IO in our Institution between 2016 and 2018 were retrospectively identified by elec-
tronic medical record review. All pts provided written informed consent for the collec-
tion of clinical, demographic and molecular data.
Results: A total number of 328 consecutive pts with KRAS mutant NSCLC were identi-
fied, of them 32 received IO. All eligible pts had PDL1 testing and in 21 cases (65.6%)
NGS was available. Median age was 63 (range 44-78). Male/female were 17/15. Most pts
had an adequate ECOG PS (0/1 18.7%/65.6% respectively). 29 pts (90.6%) were smok-
ers. According to the setting, 10 pts were treated in 1st-line, 9 in 2nd-line and 13 in fur-
ther lines. Between the 9 subtypes of KRAS mutation identified in our cohort, G12C
was the commonest (14, 43.8%). 15 pts (46.9%) had PDL150%, 10 (31.2%) had PD-
L1 between 1-49%, and 7 (21.9%) were negative. 8 pts (25%) had co-occurring gene
mutations. With a median follow-up of 5.1 mos (0.4-28.6), the mPFS and mOS for ITT
population were 4.47 (95% CI 2.5-6.4) and 7.73 (95% CI 6-14.5) mos.
Conclusions: Our preliminary results, contrary to findings in other oncogene driven
NSCLC, showed that the presence of KRAS mutations seems to be irrelevant for the
selection of patients for IO. Furthermore, neither the association of co-mutation
(found in the 25% of cases) nor the type of KRAS variant or the treatment setting (1st
vs further lines) seems to have an impact on the effectiveness of IO in KRAS NSCLC
pts. Data about clinical efficacy according to PD-L1 expression will be presented at the
meeting.
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Background: Checkpoint inhibitors plus platinum-based chemotherapy have shown
superiority compared to chemotherapy alone as first-line therapy in advanced non–
small cell lung carcinoma (NSCLC), but little is known about the real benefit within the
different PDL1 expression subgroups. Our aim was to estimate the relative benefit in
term of Overall Survival (OS) and Progression-free Survival (PFS) of checkpoint inhib-
itors plus chemotherapy versus chemotherapy alone, overall and in subgroups defined
by PDL1 expression.
Methods: This meta-analysis searched PubMed and checked references of articles to iden-
tify trials that combined checkpoint with chemotherapy versus chemotherapy in the first-
line setting. For each trial included in this study, the trial name, year of publication or con-
ference presentation, patients’ clinic-pathological characteristics, type of chemotherapy,
type of checkpoint inhibitor and PDL1 expression were extracted. Data collection took
place from October 1th to October 24th, 2018. A random-effects model was applied.
Results: Eight trials with advanced NSCLC were included in this meta-analysis.
Checkpoint inhibitors plus chemotherapy were associated with prolonged OS, com-
pared with chemotherapy in the ITT population (HR, 0.61; 95% CI, 0.61-0.66;
P<.000001). OS was prolonged in the PDL1 0% group (HR, 0.78; 95% CI, 0.67-0.90;
P<.0007) and in the PDL1 high (HR, 0.61; 95% CI, 0.48-0.78; P<.00001) but not in the
PDL1 low (HR, 0.77; 95% CI, 0.55-0.107; P< 0.12). Chemotherapy plus pembrolizu-
mab showed OS benefit (HR, 0.56; 95% CI, 0.40-0.78; P<.00007)in low PD-L1 low,
unlike atezolizumab backbone trials (HR, 0.92; 95% CI, 0.62-1.37; P< 0.69).
Checkpoint inhibitors plus chemotherapy were associated with prolonged PFS in the
ITT (HR, 0.61; 95% CI, 0.56-0.66; P< 0.00001) across PDL1 subgroups.
Conclusions: Checkpoint inhibitors plus chemotherapy compared to chemotherapy,
are associated with prolonged OS and PFS in first-line therapy in NSCLC. In low PDL1
subgroup the benefit was statistically significant only in the pembrolizumab backbone
trials. The findings of this meta-analysis could assist in the design and interpretation of
future trials and in economic analyses.
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Background: Recently, the phase 3 keynote-189 trial showed that in previously untreated
patients with advanced non-squamous NSCLC without targetable mutations, the
progression-free and overall survival were significantly longer with addition of pembroli-
zumab to chemotherapy than with chemotherapy alone. Both chemotherapy and pem-
brolizumab can give renal toxicity, which can be a major challenge in the clinical setting.
Methods: In a prospective multicenter observational real-life cohort study [Visser Eur
Respir J 2018], we evaluated the incidence of acute/chronic kidney disease (AKD/
CKD), its related treatment discontinuation frequency and associated clinical variables
with AKD in patients with stage IIIB/IV NSCLC treated with platinum/pemetrexed. In
addition, the Keynote 189 toxicity data was used for the combination treatment. We
thereafter reviewed literature to generate an algorithm for diagnosis and treatment in
increased creatinine levels.
Results: 149 patients received pemetrexed platinum, of whom 44 patients (30%) continued
maintenance. During induction therapy 48 patients (50%) treated with cisplatinum/peme-
trexed developed AKD and 15 patients (29%) treated with carboplatin/pemetrexed. During
maintenance 13 patients (30%) developed AKD, leading to CKD and treatment discontinu-
ation in eight patients (62%). In the Keynote 189 trial combining pembrolizumab with che-
motherapy, nephritis has been reported in 1,7% of patients in any grade (1,5% grade 3-4).
However, when looking at an increased blood creatinine in the group that was treated with
carboplatin, a total of 12,2% of patients showed any increase (0,7% grade 3-4).
Conclusions: Increased blood creatinine levels from pemetrexed and pembrolizumab
is a common entity, probably more common in a real-life setting. This elevation is clini-
cally challenging in a population that receives three agents that can cause a creatinine
increase. Currently, there are no markers to distinguish between renal failure due to
chemotherapy of immunotherapy. We will present an algorithm based on current
knowledge for clinicians as guidance for renal dysfunction in patients treated with che-
motherapy and pd-(l)1 checkpoint inhibitors.
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Background: IT has improved outcomes in advanced NSCLC. However, this therapy
can yield significant toxicity secondary to immune activation. Several retrospective
studies have reported a direct relationship between IT efficacy and the development of
irAEs, in Response Rate (RR) and survival.
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